Compositions comprising TLIA-Ig fusion protein for the regulation of T regulatory cells, and methods for their use
USRE48599E1 · kind E1 · reissue
0Cited by
58References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 27, 2019 |
| Grant date | Jun 22, 2021 |
| Priority date | — |
| Expiry date | Mar 27, 2039 |
Classification
- Technology area (CPC —)General
Abstract
Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.